Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M109,919Revenue (TTM) $M37,728Net Margin (%)13.6Altman Z-Score2.0
Enterprise Value $M119,414EPS (TTM) $2.0Operating Margin %18.8Piotroski F-Score4
P/E(ttm)22.1Beneish M-Score-3.1Pre-tax Margin (%)16.4Higher ROA y-yY
Price/Book1.810-y EBITDA Growth Rate %-1.9Quick Ratio0.6Cash flow > EarningsN
Price/Sales3.05-y EBITDA Growth Rate %-5.4Current Ratio1.6Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %-14.6ROA % (ttm)4.6Higher Current Ratio y-yN
Dividend Yield %3.9PEG--ROE % (ttm)8.3Less Shares Outstanding y-yY
Payout Ratio %87.0Shares Outstanding M2,574ROIC % (ttm)7.6Gross Margin Increase y-yY

Gurus Latest Trades with SNY

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

SNY is held by these investors:

SNY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Sanofi10% Owner 2015-01-29Buy97,118$95-55.42view
Sanofi10% Owner 2015-01-26Buy647,448$95-55.42view
Sanofi10% Owner 2015-01-22Buy196,251$93.17-54.55view
Sanofi10% Owner 2014-03-25Buy344,448$66.88-36.68view
Sanofi10% Owner 2014-02-04Buy1,303,780$7.67452.15view

Press Releases about SNY :

Quarterly/Annual Reports about SNY:

    News about SNY:

    Articles On GuruFocus.com
    While Big Diabetes Stagnates, Smaller Companies Are Moving Faster Than Ever Feb 09 2017 
    David Herro's Oakmark International Fund Fourth Quarter Letter Jan 11 2017 
    Something Strange Is Going On With Oral Insulin Dec 23 2016 
    Dodge & Cox Invests in 7 Positions in the 3rd Quarter Dec 19 2016 
    Warren Buffett’s Only Dividend Stocks With 4%-Plus Yields Nov 29 2016 
    World Leader in Diabetes Medication Hits 2-Year Low Nov 07 2016 
    First Eagle Investments Comments on Sanofi Oct 24 2016 
    Gilead’s Patience Is Wearing Investors' Patience Thin Oct 10 2016 
    Novo Nordisk Is Being Ignored Oct 06 2016 
    Take a Look at Sanofi Oct 05 2016 

    More From Other Websites
    Merck & Co.’s Animal Health Segment Feb 24 2017
    Teva Is Expected to See a Fall in Its Profit Margins in 2017 Feb 23 2017
    ​Ipswich consultant’s biotech training program expands into Europe Feb 22 2017
    Amgen Gets EU Nod for Monthly Repatha Dose Feb 22 2017
    What Happened to Sanofi’s Valuation after 4Q16? Feb 21 2017
    Sanofi Pasteur: Why Human Vaccines Matter Feb 21 2017
    Inside Sanofi’s Consumer Healthcare and Generics Strategy Feb 21 2017
    These Prescription Products Matter to Sanofi’s Growth Feb 20 2017
    Sanofi’s Unique Foothold in Diabetes and Cardiovascular Feb 20 2017
    This Keeps Driving Sanofi’s Growth Feb 20 2017
    Inside Sanofi’s Revenues in 4Q16 Feb 17 2017
    Parsabiv Is Expected to Boost Amgen’s Revenues in 2017 Feb 17 2017
    Sanofi Backtracked on Actelion Offer Price Amid J&J Talks Feb 16 2017
    How Sanofi lost out to J&J in $30 bln battle for Actelion Feb 16 2017
    Amicus Therapeutics Updates Migalastat Drug Feb 15 2017
    Amgen Looking to Broaden Leukemia Drug Blincyto's Label Feb 15 2017
    Sanofi to Sell 5 OTC Drugs to Ipsen for $88M Feb 13 2017

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)